IPC Alert: About adverse reactions to Meftal Painkiller

Recently, the commission issued a drug safety IPC alert that demands the attention of healthcare professionals and patients alike

The Health Master

December 7, 2023

504

Indian Pharmacopoeia Commission IPC — IPC

Table of Contents

Last Updated on December 23, 2023 by Hitesh Goyal

IPC Alert

The Indian Pharmacopoeia Commission (IPC) plays a crucial role in ensuring the safety and efficacy of pharmaceuticals in India. Recently, the commission issued a drug safety IPC alert that demands the attention of healthcare professionals and patients alike.

This IPC alert, issued on November 30, specifically addresses concerns related to the painkiller Meftal, a commonly prescribed medication for menstrual cramps and rheumatoid arthritis.

Follow us on WhtasApp Channel

Meftal: A Brief Introduction

Meftal, containing mefenamic acid, serves as a therapeutic solution for various conditions such as rheumatoid arthritis, osteoarthritis, dysmenorrhea, mild to moderate pain, inflammation, fever, and dental pain.

While widely used and effective for these purposes, recent findings have prompted the IPC to raise awareness about potential adverse reactions associated with its consumption.

Understanding DRESS Syndrome

The drug safety IPC alert highlights a preliminary analysis from the Pharmacovigilance Programme of India (PvPI) database, revealing instances of drug reactions leading to eosinophilia and systemic symptoms (DRESS) syndrome.

But what exactly is DRESS Syndrome? This section will delve into the syndrome’s definition and the specific connection between Meftal and its occurrence.

IPC Alerts

Recommendations for Vigilance

Healthcare professionals and patients are strongly advised to closely monitor the possibility of adverse drug reactions (ADRs) associated with Meftal usage.

In the event of such reactions, the IPC emphasizes the importance of reporting the matter promptly. This section will outline detailed recommendations for vigilance, ensuring the safety of those using Meftal.

Reporting Adverse Drug Reactions to PvPI

Understanding how to report adverse drug reactions is crucial for effective pharmacovigilance.

Here, we will explore the step-by-step process of filing a report on the IPC website, utilizing the ADR PvPI mobile app, and contacting the PvPI Helpline.

Clear guidelines will be provided to encourage both healthcare professionals and patients to contribute to this essential reporting system.

Click for more on (IPC) Indian Pharmacopoeia Commission

The National Coordination Centre of PvPI

This section will underscore the significance of reporting adverse reactions to the national coordination centre of the PvPI.

Addressing concerns and ensuring patient safety will be discussed to assure individuals of the impact their reports can have in maintaining the overall safety and effectiveness of medications.

IPC as an Autonomous Institution

As an autonomous institution of the Ministry of Health, the IPC plays a pivotal role in establishing standards for all drugs manufactured, sold, and consumed in India.

This section will provide insights into the IPC’s responsibilities and its affiliation with the Ministry of Health.

Conclusion

In conclusion, the drug safety IPC alert regarding Meftal serves as a vital call for vigilance in the medical community and among patients.

By understanding the potential risks associated with Meftal and actively participating in the reporting process, individuals contribute to the ongoing efforts to enhance drug safety in India.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.